Compare Natera Inc. Common Stock (NTRA) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Vanguard Total World Stock Index Fund ETF trades at $157.18 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is the larger of the two by market cap, and Vanguard Total World Stock Index Fund ETF is more actively traded (7,186,242 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Total World Stock Index Fund ETF for 54 Days on average.
| NTRA | VT | |
|---|---|---|
Market Cap | $57.03B | $101.70B |
Volume | 1,131,157 | 7,186,242 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $162.39 |
52-Week Low | $179.42 | $134.19 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Vanguard Total World Stock ETF (VT) trades at $159.76, showing modest daily gains of 0.16% with neutral technical indicators. The ETF maintains broad global diversification across 9,773 stocks with a low 0.06% expense ratio. Recent news highlights VT's strong five-year performance compared to international-focused peers, though some competitors offer lower fees. Technical analysis shows the ETF trading near pivot point resistance at $160 with support at $159.
VT provides comprehensive global equity exposure but faces fee competition from alternatives like SPDW. The ETF's broad diversification minimizes country-specific risks while capturing global growth. Key risks include expense ratio pressure and emerging market volatility. Analyst sentiment remains positive for long-term investors seeking one-stop global diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
